EAST HANOVER, N.J., Jan. 15, 2016 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) for two new indications - the treatment ...

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

Offering a new treatment option for patients, Cosentyx is the first approved human monoclonal antibody (mAb) that selectively binds to interleukin IL-17A[1],[2] Phase III data demonstrated Cosentyx ...

Cosentyx (secukinumab) is a prescription drug that’s used to treat conditions such as plaque psoriasis and psoriatic arthritis. Cosentyx is given as an injection under the skin or as an IV infusion.

Novartis’ immunology drug Cosentyx (secukinumab) notched its sixth indication, gaining U.S. approval as a hidradenitis suppurativa (HS) therapy, the drugmaker said this week. The regulatory OK makes ...

The US Food and Drug Administration (FDA) has approved secukinumab (Cosentyx, Novartis) for the treatment of active enthesitis-related arthritis (ERA) in children and adolescents age 4 years and older ...

The approval was based on data from the phase 3 SUNSHINE and SUNRISE trials, which included 1084 adults with moderate to severe HS. Results showed a significantly greater proportion of patients ...

The U.S. Food and Drug Administration today approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis. Psoriasis is a skin condition that causes patches of skin redness ...

Cosentyx for Plaque Psoriasis Approved Novartis announced that the Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for the treatment of adults with active ankylosing spondylitis ...

(RTTNews) - The U.S. Food and Drug Administration has approved Novartis' (NVS) Cosentyx or secukinumab for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and ...

Cosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as an alternative to treatments that have significant side effects[1]; all other ...

AbbVie (ABBV-0.69%) and Boehringer Ingelheim's Skyrizi performed better than Novartis' (NVS-0.32%) Cosentyx in a head-to-head late stage clinical trial in patients with the plaque psoriasis, an ...